Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-24

Clinical Trial Update: Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of perfluorohexyloctane (NOV03) for dry eye disease has been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Perfluorohexyloctane (perfluorohexyloctane)

Snippet

Sponsor: Novaliq GmbH | Conditions: Dry Eye Disease (DED) | Phase 2 | Status: COMPLETED | Results posted: 2021-05-24